<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="105229">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01734564</url>
  </required_header>
  <id_info>
    <org_study_id>CD-2010-01</org_study_id>
    <nct_id>NCT01734564</nct_id>
  </id_info>
  <brief_title>Phase II Study With Hiltonol and Dendritic Cells in Solid Tumors</brief_title>
  <official_title>Phase II Study With Hiltonol and Dendritic Cells in Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinica Universidad de Navarra, Universidad de Navarra</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this phase II study, patients with solid tumors will receive treatment with hiltonol and
      autologous dendritic cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this phase II study, patients with solid tumors will receive treatment with intratumoral
      hiltonol and two cycles of autologous dendritic cells loaded with autologous tumor and
      administered subcutaneously. A new cohort will explore the role of radiation therapy,
      looking for an abscopal effect.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>8-10 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety (Common Toxicity Criteria 4.0)</measure>
    <time_frame>8-10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Hiltonol and autologous dendritic cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hiltonol and autologous dendritic cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hiltonol, dendritic cells and radiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hiltonol, dendritic cells and radiation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hiltonol and autologous dendritic cells</intervention_name>
    <description>Hiltonol and autologous dendritic cells</description>
    <arm_group_label>Hiltonol and autologous dendritic cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hiltonol, dendritic cells and radiation</intervention_name>
    <description>Hiltonol, autologous dendritic cells and radiation therapy. Radiation therapy will pursue an abscopal effect.</description>
    <arm_group_label>Hiltonol, dendritic cells and radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of advanced solid tumors

          -  Measurable disease

          -  Performance status 0, 1 or 2.

          -  Adequate renal, hepatic and bone marrow function

          -  Availability of tumor tissue, for maturing dendritic cells

        Exclusion Criteria:

          -  Clinically relevant diseases or infections.

          -  concurrent participation in other clinical trial or administration or other
             antitumoral treatment

          -  Concurrent cancer, with the exceptions allowed by the PI.

          -  Pregnant or breast feeding women

          -  immunosuppressant treatment

          -  known uncontrolled central nervous system metastasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Luis Perez Gracia, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Universidad de Navarra</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jose Luis Perez Gracia, MD, PhD</last_name>
    <phone>+34948255400</phone>
    <phone_ext>5825</phone_ext>
    <email>jlgracia@unav.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jose Luis Perez Gracia, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 10, 2016</lastchanged_date>
  <firstreceived_date>November 21, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Poly ICLC</mesh_term>
    <mesh_term>Poly I-C</mesh_term>
    <mesh_term>Carboxymethylcellulose Sodium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
